The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes

Progress in Neurobiology

Volumn 94, Issue 4, 2011, Pages 418-460

  Drago, Antonio ^a   Crisafulli, Concetta ^b   Sidoti, Antonina ^b   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Candidate gene; Glutamate; Major depression; Monoaminergic; Variation

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; AMPA RECEPTOR AGONIST; AMPA RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; CALCINEURIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALPAIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DICER; DOPAMINE; DOPAMINE RECEPTOR; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCINE RECEPTOR ANTAGONIST; INOSITOL; KAINIC ACID RECEPTOR AGONIST; KAINIC ACID RECEPTOR ANTAGONIST; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NITRIC OXIDE; NORADRENALIN; RAP PROTEIN; RAS PROTEIN; SEROTONIN; SEROTONIN RECEPTOR; UNINDEXED DRUG;

BRAIN NERVE CELL; CELL FATE; CENTRAL NERVOUS SYSTEM; CYTOSKELETON; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG EFFICACY; GENETIC VARIABILITY; GLUTAMATERGIC SYSTEM; HUMAN; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MAJOR DEPRESSION; NERVE FIBER; NONHUMAN; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; PHENOTYPE; PHOTOTHERAPY; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

ANIMALS; BRAIN; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DEPRESSIVE DISORDER; DOPAMINE; EXCITATORY AMINO ACID AGENTS; GLUTAMIC ACID; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NEURAL PATHWAYS; NITRIC OXIDE; NOREPINEPHRINE; PHENOTYPE; PROTEIN KINASE C; RECEPTORS, DOPAMINE; SEROTONIN; SIGNAL TRANSDUCTION;

EID: 79960462899     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2011.05.009     Document Type: Review

References (447)

1. aan het Rot M., Mathew S.J., Charney D.S. Neurobiological mechanisms in major depressive disorder. Can. Med. Assoc. J. 2009, 180:305-313.
2. Addae J.I., Ali N., Youssef F.F., Stone T.W. AMPA receptor activation reduces epileptiform activity in the rat neocortex. Brain Res. 2007, 1158:151-157.
3. Adell A., Celada P., Abellan M.T., Artigas F. Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei. Brain Res. Brain Res. Rev. 2002, 39:154-180.
4. Aghajanian G.K., Marek G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 1997, 36:589-599.
5. Aghajanian G.K., Marek G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res. Brain Res. Rev. 2000, 31:302-312.
6. Ahnaou A., Dautzenberg F.M., Geys H., Imogai H., Gibelin A., Moechars D., Steckler T., Drinkenburg W.H. Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture. Eur. J. Pharmacol. 2009, 603:62-72.
7. Akin D., Manier D.H., Sanders-Bush E., Shelton R.C. Signal transduction abnormalities in melancholic depression. Int. J. Neuropsychopharmacol. 2005, 8:5-16.
8. Alagarsamy S., Lonart G., Johnson K.M. Regulation of nitric oxide synthase activity in cortical slices by excitatory amino acids and calcium. J. Neurosci. Res. 1994, 38:648-653.
9. Albers G.W., Goldstein L.B., Hall D., Lesko L.M. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. JAMA 2001, 286:2673-2682.
10. Alexander G.M., Godwin D.W. Presynaptic inhibition of corticothalamic feedback by metabotropic glutamate receptors. J. Neurophysiol. 2005, 94:163-175.
11. Amador M., Dani J.A. MK-801 inhibition of nicotinic acetylcholine receptor channels. Synapse 1991, 7:207-215.
12. Amargos-Bosch M., Lopez-Gil X., Artigas F., Adell A. Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine. Int. J. Neuropsychopharmacol. 2006, 9:565-573.
13. Amilhon B., Lepicard E., Renoir T., Mongeau R., Popa D., Poirel O., Miot S., Gras C., Gardier A.M., Gallego J., Hamon M., Lanfumey L., Gasnier B., Giros B., El Mestikawy S. VGLUT3 (vesicular glutamate transporter type 3) contribution to the regulation of serotonergic transmission and anxiety. J. Neurosci. 2010, 30:2198-2210.
14. Appel N.M., Rapoport S.I., O'Callaghan J.P., Bell J.M., Freed L.M. Sequelae of parenteral domoic acid administration in rats: comparison of effects on different metabolic markers in brain. Brain Res. 1997, 754:55-64.
15. Arai A., Guidotti A., Costa E., Lynch G. Effect of the AMPA receptor modulator IDRA 21 on LTP in hippocampal slices. Neuroreport 1996, 7:2211-2215.
16. Arai A.C., Xia Y.F., Suzuki E. Modulation of AMPA receptor kinetics differentially influences synaptic plasticity in the hippocampus. Neuroscience 2004, 123:1011-1024.
17. Araki T., Tanaka T., Tanaka S., Yonemasu Y., Kato M., Goto I. Kainic acid-induced thalamic seizure in cats-a possible model of petit mal seizure. Epilepsy Res. 1992, 13:223-229.
18. Araneda R., Andrade R. 5-Hydroxytryptamine2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 1991, 40:399-412.
19. Arnold P.D., Sicard T., Burroughs E., Richter M.A., Kennedy J.L. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch. Gen. Psychiatry 2006, 63:769-776.
20. Attwell P.J., Singh Kent N., Jane D.E., Croucher M.J., Bradford H.F. Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV). Brain Res. 1998, 805:138-143.
21. Axmacher N., Cohen M.X., Fell J., Haupt S., Dumpelmann M., Elger C.E., Schlaepfer T.E., Lenartz D., Sturm V., Ranganath C. Intracranial EEG correlates of expectancy and memory formation in the human hippocampus and nucleus accumbens. Neuron 2010, 65:541-549.
22. Bagley J., Moghaddam B. Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or diazepam. Neuroscience 1997, 77:65-73.
23. Balla A., Hashim A., Burch S., Javitt D.C., Lajtha A., Sershen H. Phencyclidine-induced dysregulation of dopamine response to amphetamine in prefrontal cortex and striatum. Neurochem. Res. 2001, 26:1001-1006.
24. Barker G.R., Warburton E.C. NMDA receptor plasticity in the perirhinal and prefrontal cortices is crucial for the acquisition of long-term object-in-place associative memory. J. Neurosci. 2008, 28:2837-2844.
25. Baron B.M., Harrison B.L., Miller F.P., McDonald I.A., Salituro F.G., Schmidt C.J., Sorensen S.M., White H.S., Palfreyman M.G. Activity of 5,7-dichlorokynurenic acid, a potent antagonist at the N-methyl-d-aspartate receptor-associated glycine binding site. Mol. Pharmacol. 1990, 38:554-561.
26. Barton A., Woolmore J.A., Ward D., Eyre S., Hinks A., Ollier W.E., Strange R.C., Fryer A.A., John S., Hawkins C.P., Worthington J. Association of protein kinase C alpha (PRKCA) gene with multiple sclerosis in a UK population. Brain 2004, 127:1717-1722.
27. Baumeister A.A., Hawkins M.F., Uzelac S.M. The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis. J. Hist. Neurosci. 2003, 12:207-220.
28. Belozertseva I.V., Kos T., Popik P., Danysz W., Bespalov A.Y. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur. Neuropsychopharmacol. 2007, 17:172-179.
29. Ben-Ari Y. Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 1985, 14:375-403.
30. Bendikov I., Nadri C., Amar S., Panizzutti R., De Miranda J., Wolosker H., Agam G. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr. Res. 2007, 90:41-51.
31. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000, 47:351-354.
32. Berridge C.W., Waterhouse B.D. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res. Brain Res. Rev. 2003, 42:33-84.
33. Besheer J., Grondin J.J., Cannady R., Sharko A.C., Faccidomo S., Hodge C.W. Metabotropic glutamate receptor 5 activity in the nucleus accumbens is required for the maintenance of ethanol self-administration in a rat genetic model of high alcohol intake. Biol. Psychiatry 2010, 67:812-822.
34. Beurrier C., Lopez S., Revy D., Selvam C., Goudet C., Lherondel M., Gubellini P., Kerkerian-LeGoff L., Acher F., Pin J.P., Amalric M. Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J. 2009, 23:3619-3628.
35. Bianchi M., Hagan J.J., Heidbreder C.A. Neuronal plasticity, stress and depression: involvement of the cytoskeletal microtubular system?. Curr. Drug Targets CNS Neurol. Disord. 2005, 4:597-611.
36. Block W., Traber F., von Widdern O., Metten M., Schild H., Maier W., Zobel A., Jessen F. Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response. Int. J. Neuropsychopharmacol. 2009, 12:415-422.
37. Blumenfeld R.S., Ranganath C. Prefrontal cortex and long-term memory encoding: an integrative review of findings from neuropsychology and neuroimaging. Neuroscientist 2007, 13:280-291.
38. Boddeke H.W., Wiederhold K.H., Palacios J.M. Intracerebroventricular application of competitive and non-competitive NMDA antagonists induce similar effects upon rat hippocampal electroencephalogram and local cerebral glucose utilization. Brain Res. 1992, 585:177-183.
39. Boeijinga P.H., Boddeke H.W. Activation of 5-HT1B receptors suppresses low but not high frequency synaptic transmission in the rat subicular cortex in vitro. Brain Res. 1996, 721:59-65.
40. Bofill-Cardona E., Kudlacek O., Yang Q., Ahorn H., Freissmuth M., Nanoff C. Binding of calmodulin to the D2-dopamine receptor reduces receptor signaling by arresting the G protein activation switch. J. Biol. Chem. 2000, 275:32672-32680.
41. Bradbury M.J., Giracello D.R., Chapman D.F., Holtz G., Schaffhauser H., Rao S.P., Varney M.A., Anderson J.J. Metabotropic glutamate receptor 5 antagonist-induced stimulation of hypothalamic-pituitary-adrenal axis activity: interaction with serotonergic systems. Neuropharmacology 2003, 44:562-572.
42. Braun I., Genius J., Grunze H., Bender A., Moller H.J., Rujescu D. Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism. Schizophr. Res. 2007, 97:254-263.
43. Brodkin J., Busse C., Sukoff S.J., Varney M.A. Anxiolytic-like activity of the mGluR5 antagonist MPEP: a comparison with diazepam and buspirone. Pharmacol. Biochem. Behav. 2002, 73:359-366.
44. Brookes K.J., Knight J., Xu X., Asherson P. DNA pooling analysis of ADHD and genes regulating vesicle release of neurotransmitters. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 139B:33-37.
45. Bruno V., Copani A., Battaglia G., Raffaele R., Shinozaki H., Nicoletti F. Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death. Eur. J. Pharmacol. 1994, 256:109-112.
46. 2+/calmodulin-dependent kinase II in prefrontal cortical pyramidal neurons. J. Biol. Chem. 2002, 277:36553-36562.
47. Calabrese F., Molteni R., Racagni G., Riva M.A. Neuronal plasticity: a link between stress and mood disorders. Psychoneuroendocrinology 2009, 34(Suppl. 1):S208-S216.
48. Calcagno E., Carli M., Invernizzi R.W. The 5-HT(1A) receptor agonist 8-OH-DPAT prevents prefrontocortical glutamate and serotonin release in response to blockade of cortical NMDA receptors. J. Neurochem. 2006, 96:853-860.
49. Cannon D.M., Klaver J.M., Peck S.A., Rallis-Voak D., Erickson K., Drevets W.C. Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112. Neuropsychopharmacology 2009, 34:1277-1287.
50. Cardinal R.N., Parkinson J.A., Hall J., Everitt B.J. Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neurosci. Biobehav. Rev. 2002, 26:321-352.
51. Cartmell J., Perry K.W., Salhoff C.R., Monn J.A., Schoepp D.D. Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade. Neuropharmacology 2001, 40:847-855.
52. Castren E., da Penha Berzaghi M., Lindholm D., Thoenen H. Differential effects of MK-801 on brain-derived neurotrophic factor mRNA levels in different regions of the rat brain. Exp. Neurol. 1993, 122:244-252.
53. Castren E., Rantamaki T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev. Neurobiol. 2010, 70:289-297.
54. Cauli O., Mlili N., Rodrigo R., Felipo V. Hyperammonaemia alters the mechanisms by which metabotropic glutamate receptors in nucleus accumbens modulate motor function. J. Neurochem. 2007, 103:38-46.
55. Celada P., Puig M.V., Casanovas J.M., Guillazo G., Artigas F. Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A, GABA(A), and glutamate receptors. J. Neurosci. 2001, 21:9917-9929.
56. Chang Y.C., Kim H.W., Rapoport S.I., Rao J.S. Chronic NMDA administration increases neuroinflammatory markers in rat frontal cortex: cross-talk between excitotoxicity and neuroinflammation. Neurochem. Res. 2008, 33:2318-2323.
57. Chapman A.G., Talebi A., Yip P.K., Meldrum B.S. Anticonvulsant activity of a mGlu(4alpha) receptor selective agonist, (1S,3R,4S)-1-aminocyclopentane-1,2,4-tricarboxylic acid. Eur. J. Pharmacol. 2001, 424:107-113.
58. Chavez-Noriega L.E., Stevens C.F. Increased transmitter release at excitatory synapses produced by direct activation of adenylate cyclase in rat hippocampal slices. J. Neurosci. 1994, 14:310-317.
59. Chen H.J., Rojas-Soto M., Oguni A., Kennedy M.B. A synaptic Ras-GTPase activating protein (p135 SynGAP) inhibited by CaM kinase II. Neuron 1998, 20:895-904.
60. Chen S.Y., Cheng H.J. Functions of axon guidance molecules in synapse formation. Curr. Opin. Neurobiol. 2009, 19:471-478.
61. 2+ channel activity in area CA1 of hippocampus. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:6467-6471.
62. Chetkovich D.M., Sweatt J.D. nMDA receptor activation increases cyclic AMP in area CA1 of the hippocampus via calcium/calmodulin stimulation of adenylyl cyclase. J. Neurochem. 1993, 61:1933-1942.
63. Chi H., Jang J.K., Kim J.H., Vezina P. Blockade of group II metabotropic glutamate receptors in the nucleus accumbens produces hyperlocomotion in rats previously exposed to amphetamine. Neuropharmacology 2006, 51:986-992.
64. Cho H.J., Kim J.G., Lee J.Y., Lee S., Jahng J.W. Repetitive dextromethorphan at adolescence affects water maze learning in female rats. Int. J. Neurosci. 2006, 116:91-101.
65. Cho Z.H., Kim Y.B., Han J.Y., Kim N.B., Hwang S.I., Kim S.J., Cho S.J. Altered T2* relaxation time of the hippocampus in major depressive disorder: Implications of ultra-high field magnetic resonance imaging. J. Psychiatr. Res. 2010.
66. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988, 1:623-634.
67. Christoffersen G.R., Christensen L.H., Hammer P., Vang M. The class I metabotropic glutamate receptor antagonist. AIDA, improves short-term and impairs long-term memory in a spatial task for rats. Neuropharmacology 1999, 38:817-823.
68. Chung R.S., McCormack G.H., King A.E., West A.K., Vickers J.C. Glutamate induces rapid loss of axonal neurofilament proteins from cortical neurons in vitro. Exp. Neurol. 2005, 193:481-488.
69. Ciccone M.A., Timmons M., Phillips A., Quick M.W. Calcium/calmodulin-dependent kinase II regulates the interaction between the serotonin transporter and syntaxin 1A. Neuropharmacology 2008, 55:763-770.
70. Cichon S., Nothen M.M., Rietschel M., Korner J., Propping P. Single-strand conformation analysis (SSCA) of the dopamine D1 receptor gene (DRD1) reveals no significant mutation in patients with schizophrenia and manic depression. Biol. Psychiatry 1994, 36:850-853.
71. Clarke P., Tyler K.L. Apoptosis in animal models of virus-induced disease. Nat. Rev. Microbiol. 2009, 7:144-155.
72. Clarke P.B., Reuben M. Inhibition by dizocilpine (MK-801) of striatal dopamine release induced by MPTP and MPP+: possible action at the dopamine transporter. Br. J. Pharmacol. 1995, 114:315-322.
73. Coan E.J., Saywood W., Collingridge G.L. MK-801 blocks NMDA receptor-mediated synaptic transmission and long term potentiation in rat hippocampal slices. Neurosci. Lett. 1987, 80:111-114.
74. Collins G.G., Anson J., Probett G.A. Excitatory and inhibitory effects of dopamine on synaptic transmission in the rat olfactory cortex slice. Brain Res. 1985, 333:237-245.
75. Cotter T.G. Apoptosis and cancer: the genesis of a research field. Nat. Rev. Cancer 2009, 9:501-507.
76. Craddock N., Kendler K., Neale M., Nurnberger J., Purcell S., Rietschel M., Perlis R., Santangelo S.L., Schulze T.G., Smoller J.W., Thapar A. Dissecting the phenotype in genome-wide association studies of psychiatric illness. Br. J. Psychiatry 2009, 195:97-99.
77. Craddock N., Owen M.J. Rethinking psychosis: the disadvantages of a dichotomous classification now outweigh the advantages. World Psychiatry 2007, 6:84-91.
78. Craven R. Ketamine. Anaesthesia 2007, 62(Suppl. 1):48-53.
79. Cryan J.F., Kelly P.H., Neijt H.C., Sansig G., Flor P.J., van Der Putten H. Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur. J. Neurosci. 2003, 17:2409-2417.
80. Cuomo D., Martella G., Barabino E., Platania P., Vita D., Madeo G., Selvam C., Goudet C., Oueslati N., Pin J.P., Acher F., Pisani A., Beurrier C., Melon C., Kerkerian-Le Goff L., Gubellini P. Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment. J. Neurochem. 2009, 109:1096-1105.
81. Dahlstrom A., Fuxe K. Localization of monoamines in the lower brain stem. Experientia 1964, 20:398-399.
82. Dakshinamurti K., Sharma S.K., Sundaram M., Watanabe T. Hippocampal changes in developing postnatal mice following intrauterine exposure to domoic acid. J. Neurosci. 1993, 13:4486-4495.
83. Danysz W., Parsons C.G. Glycine and N-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol. Rev. 1998, 50:597-664.
84. Darlington C.L. Dexanabinol: a novel cannabinoid with neuroprotective properties. IDrugs 2003, 6:976-979.
85. Davis M., Shi C. The extended amygdala: are the central nucleus of the amygdala and the bed nucleus of the stria terminalis differentially involved in fear versus anxiety?. Ann. N.Y. Acad. Sci. 1999, 877:281-291.
86. Davis T.H., Cuellar T.L., Koch S.M., Barker A.J., Harfe B.D., McManus M.T., Ullian E.M. Conditional loss of Dicer disrupts cellular and tissue morphogenesis in the cortex and hippocampus. J. Neurosci. 2008, 28:4322-4330.
87. Dawson L., Chadha A., Megalou M., Duty S. The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat. Br. J. Pharmacol. 2000, 129:541-546.
88. Dawson L.A., Nguyen H.Q., Li P. The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 2001, 25:662-668.
89. Dawson V.L., Dawson T.M. Physiological and toxicological actions of nitric oxide in the central nervous system. Adv. Pharmacol. 1995, 34:323-342.
90. De A., Krueger J.M., Simasko S.M. Glutamate induces the expression and release of tumor necrosis factor-alpha in cultured hypothalamic cells. Brain Res. 2005, 1053:54-61.
91. De Foubert G., Carney S.L., Robinson C.S., Destexhe E.J., Tomlinson R., Hicks C.A., Murray T.K., Gaillard J.P., Deville C., Xhenseval V., Thomas C.E., O'Neill M.J., Zetterstrom T.S. Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience 2004, 128:597-604.
92. De La Garza R., Jentsch J.D., Verrico C.D., Roth R.H. Adaptation of monoaminergic responses to phencyclidine in nucleus accumbens and prefrontal cortex following repeated treatment with fluoxetine or imipramine. Brain Res. 2002, 958:20-27.
93. 2+/calmodulin-kinase II enhances channel conductance of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate type glutamate receptors. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:3269-3274.
94. Di Liberto V., Bonomo A., Frinchi M., Belluardo N., Mudo G. Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain. Neuroscience 2010, 165:863-873.
95. Dickel D.E., Veenstra-VanderWeele J., Cox N.J., Wu X., Fischer D.J., Van Etten-Lee M., Himle J.A., Leventhal B.L., Cook E.H., Hanna G.L. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch. Gen. Psychiatry 2006, 63:778-785.
96. Divish M.M., Sheftel G., Boyle A., Kalasapudi V.D., Papolos D.F., Lachman H.M. Differential effect of lithium on fos protooncogene expression mediated by receptor and postreceptor activators of protein kinase C and cyclic adenosine monophosphate: model for its antimanic action. J. Neurosci. Res. 1991, 28:40-48.
97. Doherty J.J., Alagarsamy S., Bough K.J., Conn P.J., Dingledine R., Mott D.D. Metabotropic glutamate receptors modulate feedback inhibition in a developmentally regulated manner in rat dentate gyrus. J. Physiol. 2004, 561:395-401.
98. Dong C., Wong M.L., Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol. Psychiatry 2009, 14:1105-1118.
99. Dougherty D.D., Bonab A.A., Ottowitz W.E., Livni E., Alpert N.M., Rauch S.L., Fava M., Fischman A.J. Decreased striatal D1 binding as measured using PET and [11C]SCH 23,390 in patients with major depression with anger attacks. Depress. Anxiety 2006, 23:175-177.
100. Drago A., Alboni S., Brunello N., De Ronchi D., Serretti A. HTR1B as a risk profile maker in psychiatric disorders: a review through motivation and memory. Eur. J. Clin. Pharmacol. 2010, 66:5-27.
101. Dunah A.W., Standaert D.G. Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J. Neurosci. 2001, 21:5546-5558.
102. Dunn J.M., Inderwies B.R., Licata S.C., Pierce R.C. Repeated administration of AMPA or a metabotropic glutamate receptor agonist into the rat ventral tegmental area augments the subsequent behavioral hyperactivity induced by cocaine. Psychopharmacology (Berl) 2005, 179:172-180.
103. Duran R., Arufe M.C., Arias B., Alfonso M. Effect of domoic acid on brain amino acid levels. Rev. Esp. Fisiol. 1995, 51:23-27.
104. Dwivedi Y., Rizavi H.S., Shukla P.K., Lyons J., Faludi G., Palkovits M., Sarosi A., Conley R.R., Roberts R.C., Tamminga C.A., Pandey G.N. Protein kinase A in postmortem brain of depressed suicide victims: altered expression of specific regulatory and catalytic subunits. Biol. Psychiatry 2004, 55:234-243.
105. Eaton S.A., Salt T.E. Modulatory effects of serotonin on excitatory amino acid responses and sensory synaptic transmission in the ventrobasal thalamus. Neuroscience 1989, 33:285-292.
106. Eker C., Gonul A.S. Volumetric MRI studies of the hippocampus in major depressive disorder: meanings of inconsistency and directions for future research. World J. Biol. Psychiatry 2010, 11:19-35.
107. Eker M.C., Kitis O., Okur H., Eker O.D., Ozan E., Isikli S., Akarsu N., Gonul A.S. Smaller hippocampus volume is associated with short variant of 5-HTTLPR polymorphism in medication-free major depressive disorder patients. Neuropsychobiology 2011, 63:22-28.
108. English J.D., Sweatt J.D. Activation of p42 mitogen-activated protein kinase in hippocampal long term potentiation. J. Biol. Chem. 1996, 271:24329-24332.
109. Evstratova A.A., Mironova E.V., Dvoretskova E.A., Antonov S.M. Apoptosis and the receptor specificity of its mechanisms during the neurotoxic action of glutamate. Neurosci. Behav. Physiol. 2009, 39:353-362.
110. Feenstra M.G., Botterblom M.H., van Uum J.F. Local activation of metabotropic glutamate receptors inhibits the handling-induced increased release of dopamine in the nucleus accumbens but not that of dopamine or noradrenaline in the prefrontal cortex: comparison with inhibition of ionotropic receptors. J. Neurochem. 1998, 70:1104-1113.
111. Fei Z., Zhang X., Bai H.M., Jiang X.F., Wang X.L. Metabotropic glutamate receptor antagonists and agonists: potential neuroprotectors in diffuse brain injury. J. Clin. Neurosci. 2006, 13:1023-1027.
112. Ferre S., Popoli P., Rimondini R., Reggio R., Kehr J., Fuxe K. Adenosine A2A and group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D2 receptors in the rat striatum. Neuropharmacology 1999, 38:129-140.
113. Ferrer-Allado T., Brechner V.L., Dymond A., Cozen H., Crandall P. Ketamine-induced electroconvulsive phenomena in the human limbic and thalamic regions. Anesthesiology 1973, 38:333-344.
114. Ferry B., Magistretti P.J., Pralong E. Noradrenaline modulates glutamate-mediated neurotransmission in the rat basolateral amygdala in vitro. Eur. J. Neurosci. 1997, 9:1356-1364.
115. ffRench-Mullen J.M., Lehmann J., Bohacek R., Fisher R.S. Tiletamine is a potent inhibitor of N-methyl-aspartate-induced depolarizations in rat hippocampus and striatum. J. Pharmacol. Exp. Ther. 1987, 243:915-920.
116. Fiorentini C., Missale C. Oligomeric assembly of dopamine D1 and glutamate NMDA receptors: molecular mechanisms and functional implications. Biochem. Soc. Trans. 2004, 32:1025-1028.
117. 2+ antagonizes alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-induced brain damage and convulsions. Eur. J. Pharmacol. 1993, 232:121-124.
118. Fitzjohn S.M., Irving A.J., Palmer M.J., Harvey J., Lodge D., Collingridge G.L. Activation of group I mGluRs potentiates NMDA responses in rat hippocampal slices. Neurosci. Lett. 1996, 203:211-213.
119. Fowler J.H., McCracken E., Dewar D., McCulloch J. Intracerebral injection of AMPA causes axonal damage in vivo. Brain Res. 2003, 991:104-112.
120. Fowler J.H., Whalley K., Murray T., O'Neill M., McCulloch J.J. The AMPA receptor potentiator LY404187 increases cerebral glucose utilization and c-fos expression in the rat. J. Cereb. Blood Flow Metab. 2004, 24:1098-1109.
121. Fukuda H., Tanaka T., Kaijima M., Nakai H., Yonemasu Y. Quisqualic acid-induced hippocampal seizures in unanesthetized cats. Neurosci. Lett. 1985, 59:53-59.
122. Gadow K.D., Roohi J., DeVincent C.J., Kirsch S., Hatchwell E. Brief report: glutamate transporter gene (SLC1A1) single nucleotide polymorphism (rs301430) and repetitive behaviors and anxiety in children with autism spectrum disorder. J. Autism Dev. Disord. 2010, 40:1139-1145.
123. Galici R., Jones C.K., Hemstapat K., Nong Y., Echemendia N.G., Williams L.C., de Paulis T., Conn P.J. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J. Pharmacol. Exp. Ther. 2006, 318:173-185.
124. Gandolfi O., Dall'Olio R., Roncada P., Montanaro N. NMDA antagonists interact with 5-HT-stimulated phosphatidylinositol metabolism and impair passive avoidance retention in the rat. Neurosci. Lett. 1990, 113:304-308.
125. Gasparini F., Bruno V., Battaglia G., Lukic S., Leonhardt T., Inderbitzin W., Laurie D., Sommer B., Varney M.A., Hess S.D., Johnson E.C., Kuhn R., Urwyler S., Sauer D., Portet C., Schmutz M., Nicoletti F., Flor P.J. (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J. Pharmacol. Exp. Ther. 1999, 289:1678-1687.
126. Giovannelli L., Casamenti F., Pepeu G. C-fos expression in the rat nucleus basalis upon excitotoxic lesion with quisqualic acid: a study in adult and aged animals. J. Neural Transm. 1998, 105:935-948.
127. Gladding C.M., Fitzjohn S.M., Molnar E. Metabotropic glutamate receptor-mediated long-term depression: molecular mechanisms. Pharmacol. Rev. 2009, 61:395-412.
128. Goddard A.W., Ball S.G., Martinez J., Robinson M.J., Yang C.R., Russell J.M., Shekhar A. Current perspectives of the roles of the central norepinephrine system in anxiety and depression. Depress. Anxiety 2010, 27:339-350.
129. Goforth H.W., Holsinger T. Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. J. ECT 2007, 23:23-25.
130. Goldstein L.S. Do disorders of movement cause movement disorders and dementia?. Neuron 2003, 40:415-425.
131. Golembiowska K., Konieczny J., Ossowska K., Wolfarth S. The role of striatal metabotropic glutamate receptors in degeneration of dopamine neurons: review article. Amino Acids 2002, 23:199-205.
132. Gomes A.R., Cunha P., Nuriya M., Faro C.J., Huganir R.L., Pires E.V., Carvalho A.L., Duarte C.B. Metabotropic glutamate and dopamine receptors co-regulate AMPA receptor activity through PKA in cultured chick retinal neurones: effect on GluR4 phosphorylation and surface expression. J. Neurochem. 2004, 90:673-682.
133. Gonzalez-Islas C., Hablitz J.J. Dopamine enhances EPSCs in layer II-III pyramidal neurons in rat prefrontal cortex. J. Neurosci. 2003, 23:867-875.
134. Goulart B.K., de Lima M.N., de Farias C.B., Reolon G.K., Almeida V.R., Quevedo J., Kapczinski F., Schroder N., Roesler R. Ketamine impairs recognition memory consolidation and prevents learning-induced increase in hippocampal brain-derived neurotrophic factor levels. Neuroscience 2010, 167:969-973.
135. Gras C., Herzog E., Bellenchi G.C., Bernard V., Ravassard P., Pohl M., Gasnier B., Giros B., El Mestikawy S. A third vesicular glutamate transporter expressed by cholinergic and serotoninergic neurons. J. Neurosci. 2002, 22:5442-5451.
136. 2+/calmodulin-dependent protein kinase II in cultured prefrontal cortical neurons. Mol. Pharmacol. 2006, 69:813-822.
137. Guimaraes F.S., Carobrez A.P., De Aguiar J.C., Graeff F.G. Anxiolytic effect in the elevated plus-maze of the NMDA receptor antagonist AP7 microinjected into the dorsal periaqueductal grey. Psychopharmacology (Berl) 1991, 103:91-94.
138. Gupta Y.K., Briyal S. Protective effect of vineatrol against kainic acid induced seizures, oxidative stress and on the expression of heat shock proteins in rats. Eur. Neuropsychopharmacol. 2006, 16:85-91.
139. Hackler E.A., Byun N.E., Jones C.K., Williams J.M., Baheza R., Sengupta S., Grier M.D., Avison M., Conn P.J., Gore J.C. Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation. Neuroscience 2010, 168:209-218.
140. Hampson R.E., Rogers G., Lynch G., Deadwyler S.A. Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity. J. Neurosci. 1998, 18:2748-2763.
141. Hardingham G.E. Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem. Soc. Trans. 2009, 37:1147-1160.
142. Harte M.K., Cahir M., Reynolds G.P., Gartlon J.E., Jones D.N. Sub-chronic phencyclidine administration increases brain-derived neurotrophic factor in the RAT hippocampus. Schizophr. Res. 2007, 94:371-372.
143. Hashimoto K., Engberg G., Shimizu E., Nordin C., Lindstrom L.H., Iyo M. Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:767-769.
144. Hashimoto R., Numakawa T., Ohnishi T., Kumamaru E., Yagasaki Y., Ishimoto T., Mori T., Nemoto K., Adachi N., Izumi A., Chiba S., Noguchi H., Suzuki T., Iwata N., Ozaki N., Taguchi T., Kamiya A., Kosuga A., Tatsumi M., Kamijima K., Weinberger D.R., Sawa A., Kunugi H. Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling. Hum. Mol. Genet. 2006, 15:3024-3033.
145. Hasuo H., Matsuoka T., Akasu T. Activation of presynaptic 5-hydroxytryptamine 2A receptors facilitates excitatory synaptic transmission via protein kinase C in the dorsolateral septal nucleus. J. Neurosci. 2002, 22:7509-7517.
146. Haug K., Kremerskothen J., Hallmann K., Sander T., Dullinger J., Rau B., Beyenburg S., Lentze M.J., Barnekow A., Elger C.E., Propping P., Heils A. Mutation screening of the chromosome 8q24.3-human activity-regulated cytoskeleton-associated gene (ARC) in idiopathic generalized epilepsy. Mol. Cell Probes 2000, 14:255-260.
147. Heidbreder C.A., Bianchi M., Lacroix L.P., Faedo S., Perdona E., Remelli R., Cavanni P., Crespi F. Evidence that the metabotropic glutamate receptor 5 antagonist MPEP may act as an inhibitor of the norepinephrine transporter in vitro and in vivo. Synapse 2003, 50:269-276.
148. Heldt S.A., Stanek L., Chhatwal J.P., Ressler K.J. Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol. Psychiatry 2007, 12:656-670.
149. Hettema J.M., An S.S., van den Oord E.J., Neale M.C., Kendler K.S., Chen X. Association study of CREB1 with major depressive disorder and related phenotypes. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009, 150B:1128-1132.
150. Hetzenauer A., Corti C., Herdy S., Corsi M., Ferraguti F., Singewald N.A Individual contribution of metabotropic glutamate receptor (mGlu) 2 and 3 to c-Fos expression pattern evoked by mGlu2/3 antagonism. Psychopharmacology (Berl) 2008, 201:1-13.
151. Higgins G.A., Breysse N., Undzys E., Kuo C., Joharchi N., Derksen D.R., Xin T., Isaac M., Slassi M. The anti-epileptic drug lacosamide (Vimpat) has anxiolytic property in rodents. Eur. J. Pharmacol. 2009, 624:1-9.
152. Hoeppner J., Prudente-Morrissey L., Herpertz S.C., Benecke R., Walter U. Substantia nigra hyperechogenicity in depressive subjects relates to motor asymmetry and impaired word fluency. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259:92-97.
153. 2+)-calmodulin-dependent protein kinase II activity in rat hippocampal slices. Zhongguo Yao Li Xue Bao 1999, 20:902-906.
154. Huang C.C., Hsu K.S., Gean P.W. Isoproterenol potentiates synaptic transmission primarily by enhancing presynaptic calcium influx via P- and/or Q-type calcium channels in the rat amygdala. J. Neurosci. 1996, 16:1026-1033.
155. Huang L.Q., Rowan M.J., Anwyl R. mGluR II agonist inhibition of LTP induction, and mGluR II antagonist inhibition of LTD induction, in the dentate gyrus in vitro. Neuroreport 1997, 8:687-693.
156. Huang Y.Y., Kandel E.R. Modulation of both the early and the late phase of mossy fiber LTP by the activation of beta-adrenergic receptors. Neuron 1996, 16:611-617.
157. Huang Y.Y., Li X.C., Kandel E.R. cAMP contributes to mossy fiber LTP by initiating both a covalently mediated early phase and macromolecular synthesis-dependent late phase. Cell 1994, 79:69-79.
158. Iken K., Chheng S., Fargin A., Goulet A.C., Kouassi E. Serotonin upregulates mitogen-stimulated B lymphocyte proliferation through 5-HT1A receptors. Cell Immunol. 1995, 163:1-9.
159. Ikonomidou C., Turski L. Pharmacology of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo-(F)-quinoxaline. Ann. N.Y. Acad. Sci. 1997, 825:394-402.
160. Ikonomidou C., Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?. Lancet Neurol. 2002, 1:383-386.
161. Imperato A., Honore T., Jensen L.H. Dopamine release in the nucleus caudatus and in the nucleus accumbens is under glutamatergic control through non-NMDA receptors: a study in freely-moving rats. Brain Res. 1990, 530:223-228.
162. Izumi Y., Zorumski C.F. Norepinephrine promotes long-term potentiation in the adult rat hippocampus in vitro. Synapse 1999, 31:196-202.
163. Jafari-Sabet M. NMDA receptor blockers prevents the facilitatory effects of post-training intra-dorsal hippocampal NMDA and physostigmine on memory retention of passive avoidance learning in rats. Behav. Brain Res. 2006, 169:120-127.
164. Jahng J.W., Zhang T.Y., Lee S., Kim D.G. Effects of dextromethorphan on nocturnal behavior and brain c-Fos expression in adolescent rats. Eur. J. Pharmacol. 2001, 431:47-52.
165. Jardim M.C., Guimaraes F.S. Role of glutamate ionotropic receptors in the dorsomedial hypothalamic nucleus on anxiety and locomotor behavior. Pharmacol. Biochem. Behav. 2004, 79:541-546.
166. Javitt D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol. Psychiatry 2004, 9. 984-997, 979.
167. Jayanthi L.D., Ramamoorthy S., Mahesh V.B., Leibach F.H., Ganapathy V. Calmodulin-dependent regulation of the catalytic function of the human serotonin transporter in placental choriocarcinoma cells. J. Biol. Chem. 1994, 269:14424-14429.
168. Jesse C.R., Savegnago L., Rocha J.B., Nogueira C.W. Neuroprotective effect caused by MPEP, an antagonist of metabotropic glutamate receptor mGluR5, on seizures induced by pilocarpine in 21-day-old rats. Brain Res. 2008, 1198:197-203.
169. Joiner M.L., Lise M.F., Yuen E.Y., Kam A.Y., Zhang M., Hall D.D., Malik Z.A., Qian H., Chen Y., Ulrich J.D., Burette A.C., Weinberg R.J., Law P.Y., El-Husseini A., Yan Z., Hell J.W. Assembly of a beta2-adrenergic receptor-GluR1 signalling complex for localized cAMP signalling. EMBO J. 2010, 29:482-495.
170. Jung M.W., Baeg E.H., Kim M.J., Kim Y.B., Kim J.J. Plasticity and memory in the prefrontal cortex. Rev. Neurosci. 2008, 19:29-46.
171. Kabuto H., Yokoi I., MoonSuk S., Yamamoto M., Mori A. Effects of kainic acid, quisqualic acid, and their antagonist, pCB-PzDA, on rat electrocorticograms and monoamine metabolite levels in rat striatum. Neurochem. Res. 1994, 19:267-274.
172. Kaijima M., Tanaka T., Yonemasu Y. Epileptogenic properties of quisqualic acid: microinjection into the unilateral amygdala in cats. No To Shinkei 1987, 39:971-976.
173. Kapur S., Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med. 2001, 52:503-517.
174. Kapus G.L., Gacsalyi I., Vegh M., Kompagne H., Hegedus E., Leveleki C., Harsing L.G., Barkoczy J., Bilkei-Gorzo A., Levay G. Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents: effects of GYKI 52466 and its novel analogues. Psychopharmacology (Berl) 2008, 198:231-241.
175. Karasawa J., Yoshimizu T., Chaki S. A metabotropic glutamate 2/3 receptor antagonist. MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell. Neurosci. Lett. 2006, 393:127-130.
176. Katsuki H., Nonaka M., Shirakawa H., Kume T., Akaike A. Endogenous d-serine is involved in induction of neuronal death by N-methyl-d-aspartate and simulated ischemia in rat cerebrocortical slices. J. Pharmacol. Exp. Ther. 2004, 311:836-844.
177. Kawashima N., Karasawa J., Shimazaki T., Chaki S., Okuyama S., Yasuhara A., Nakazato A. Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors. Neurosci. Lett. 2005, 378:131-134.
178. Kegeles L.S., Abi-Dargham A., Zea-Ponce Y., Rodenhiser-Hill J., Mann J.J., Van Heertum R.L., Cooper T.B., Carlsson A., Laruelle M. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol. Psychiatry 2000, 48:627-640.
179. 2+/calmodulin-dependent protein kinase. Proc. Natl. Acad. Sci. U.S.A. 1984, 81:945-949.
180. Kim H.W., Chang Y.C., Chen M., Rapoport S.I., Rao J.S. Chronic NMDA administration to rats increases brain pro-apoptotic factors while decreasing anti-Apoptotic factors and causes cell death. BMC Neurosci. 2009, 10:123.
181. Kim M., Campeau S., Falls W.A., Davis M. Infusion of the non-NMDA receptor antagonist CNQX into the amygdala blocks the expression of fear-potentiated startle. Behav. Neural Biol. 1993, 59:5-8.
182. Klausnitzer J., Kulla A., Manahan-Vaughan D. Role of the group III metabotropic glutamate receptor in LTP, depotentiation and LTD in dentate gyrus of freely moving rats. Neuropharmacology 2004, 46:160-170.
183. Klimek V., Schenck J.E., Han H., Stockmeier C.A., Ordway G.A. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol. Psychiatry 2002, 52:740-748.
184. Kniest A., Wiesenberg C., Weber B., Colla M., Heuser I., Deuschle M. The glutamate antagonist riluzole and its effects upon basal and stress-induced activity of the human hypothalamus-pituitary-adrenocortical system in elderly subjects. Neuropsychobiology 2001, 43:91-95.
185. Knuesel I., Elliott A., Chen H.J., Mansuy I.M., Kennedy M.B. A role for synGAP in regulating neuronal apoptosis. Eur. J. Neurosci. 2005, 21:611-621.
186. Kolber B.J., Montana M.C., Carrasquillo Y., Xu J., Heinemann S.F., Muglia L.J., Gereau R.W.t. Activation of metabotropic glutamate receptor 5 in the amygdala modulates pain-like behavior. J. Neurosci. 2010, 30:8203-8213.
187. Kramer M.S., Last B., Getson A., Reines S.A. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Arch. Gen. Psychiatry 1997, 54:567-572.
188. Krystal J.H., Sanacora G., Blumberg H., Anand A., Charney D.S., Marek G., Epperson C.N., Goddard A., Mason G.F. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol. Psychiatry 2002, 7(Suppl. 1):S71-S80.
189. Kudoh A., Takahira Y., Katagai H., Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth. Analg. 2002, 95:114-118. (table of contents).
190. Kwon J.S., Joo Y.H., Nam H.J., Lim M., Cho E.Y., Jung M.H., Choi J.S., Kim B., Kang D.H., Oh S., Park T., Hong K.S. Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch. Gen. Psychiatry 2009, 66:1233-1241.
191. Laabich A., Cooper N.G. Regulation of calcium/calmodulin-dependent protein kinase II in the adult rat retina is mediated by ionotropic glutamate receptors. Exp. Eye Res. 1999, 68:703-713.
192. Lacaille J.C., Harley C.W. The action of norepinephrine in the dentate gyrus: beta-mediated facilitation of evoked potentials in vitro. Brain Res. 1985, 358:210-220.
193. Lacaille J.C., Schwartzkroin P.A. Intracellular responses of rat hippocampal granule cells in vitro to discrete applications of norepinephrine. Neurosci. Lett. 1988, 89:176-181.
194. Laje G., Perlis R.H., Rush A.J., McMahon F.J. Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr. Serv. 2009, 60:1446-1457.
195. Larsen M.H., Olesen M., Woldbye D.P., Hay-Schmidt A., Hansen H.H., Ronn L.C., Mikkelsen J.D. Regulation of activity-regulated cytoskeleton protein (Arc) mRNA after acute and chronic electroconvulsive stimulation in the rat. Brain Res. 2005, 1064:161-165.
196. Lecrux C., Nicole O., Chazalviel L., Catone C., Chuquet J., MacKenzie E.T., Touzani O. Spontaneously hypertensive rats are highly vulnerable to AMPA-induced brain lesions. Stroke 2007, 38:3007-3015.
197. Lee C.C., Lin Y.Y., Hsu C.W., Chu S.J., Tsai S.H. Movement disorder caused by abuse of veterinary anesthesia containing tiletamine. Am. J. Emerg. Med. 2009, 27. 1022, e1025-1026.
198. Lee H.K., Takamiya K., He K., Song L., Huganir R.L. Specific roles of AMPA receptor subunit GluR1 (GluA1) phosphorylation sites in regulating synaptic plasticity in the CA1 region of hippocampus. J. Neurophysiol. 2010, 103:479-489.
199. Lee J.H., Lee J., Choi K.Y., Hepp R., Lee J.Y., Lim M.K., Chatani-Hinze M., Roche P.A., Kim D.G., Ahn Y.S., Kim C.H., Roche K.W. Calmodulin dynamically regulates the trafficking of the metabotropic glutamate receptor mGluR5. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:12575-12580.
200. Lee J.W., Furmanski O., Castellanos D.A., Daniels L.A., Hama A.T., Sagen J. Prolonged nociceptive responses to hind paw formalin injection in rats with a spinal cord injury. Neurosci. Lett. 2008, 439:212-215.
201. Lee S., Jeong J., Kwak Y., Park S.K. Depression research: where are we now?. Mol. Brain 2010, 3:8.
202. Lee S.H., Govindaiah G., Cox C.L. Selective excitatory actions of Dnqx and Cnqx in rat thalamic neurons. J. Neurophysiol. 2010.
203. Legutko B., Szewczyk B., Pomierny-Chamiolo L., Nowak G., Pilc A. Effect of MPEP treatment on brain-derived neurotrophic factor gene expression. Pharmacol. Rep. 2006, 58:427-430.
204. Leipnitz G., da Silva Lde B., Fernandes C.G., Seminotti B., Amaral A.U., Dutra-Filho C.S., Wajner M. d-Serine administration provokes lipid oxidation and decreases the antioxidant defenses in rat striatum. Int. J. Dev. Neurosci. 2010, 28:297-301.
205. Lejeune F., Gobert A., Rivet J.M., Millan M.J. Blockade of transmission at NMDA receptors facilitates the electrical and synthetic activity of ascending serotoninergic neurones. Brain Res. 1994, 656:427-431.
206. Li P., Kerchner G.A., Sala C., Wei F., Huettner J.E., Sheng M., Zhuo M. AMPA receptor-PDZ interactions in facilitation of spinal sensory synapses. Nat. Neurosci. 1999, 2:972-977.
207. Li X., Tizzano J.P., Griffey K., Clay M., Lindstrom T., Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 2001, 40:1028-1033.
208. Liang K.C., Lin M.H., Tyan Y.M. Involvement of amygdala N-methyl-d-asparate receptors in long-term retention of an inhibitory avoidance response in rats. Chin. J. Physiol. 1993, 36:47-56.
209. Lin C.H., Lee C.C., Huang Y.C., Wang S.J., Gean P.W. Activation of group II metabotropic glutamate receptors induces depotentiation in amygdala slices and reduces fear-potentiated startle in rats. Learn. Mem. 2005, 12:130-137.
210. Lin Y., Fossom L.H., Skolnick P., Long J.B. Sustained exposure to a glycine receptor partial agonist differentially alters NMDA receptor agonist and antagonist potencies in cultured spinal cord neurons. Eur. J. Pharmacol. 1998, 356:255-260.
211. Lindefors N., Barati S., O'Connor W.T. Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex. Brain Res. 1997, 759:205-212.
212. Linden A.M., Greene S.J., Bergeron M., Schoepp D.D. Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions. Neuropsychopharmacology 2004, 29:502-513.
213. Lintas C., Sacco R., Garbett K., Mirnics K., Militerni R., Bravaccio C., Curatolo P., Manzi B., Schneider C., Melmed R., Elia M., Pascucci T., Puglisi-Allegra S., Reichelt K.L., Persico A.M. Involvement of the PRKCB1 gene in autistic disorder: significant genetic association and reduced neocortical gene expression. Mol. Psychiatry 2009, 14:705-718.
214. Lisman J.E. A mechanism for memory storage insensitive to molecular turnover: a bistable autophosphorylating kinase. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:3055-3057.
215. Liu S., Bubar M.J., Lanfranco M.F., Hillman G.R., Cunningham K.A. Serotonin2C receptor localization in GABA neurons of the rat medial prefrontal cortex: implications for understanding the neurobiology of addiction. Neuroscience 2007, 146:1677-1688.
216. Liu X.H., Xu Y.F., Cui D.H., Jiang S.D., Qian Y.P., Yu S.Y., Jiang K.D. Association of cyclic adenosine monophosphate response element-binding protein gene and major depressive disorder. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2010, 27:263-266.
217. Liukaitis V. Influence of adrenoreceptors on functions of the body. Medicina (Kaunas) 2005, 41:713-723.
218. Lopez-Gil X., Artigas F., Adell A. Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action. Int. J. Neuropsychopharmacol. 2009, 12:487-499.
219. Lopez-Gil X., Artigas F., Adell A. Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex. Curr. Pharm. Des. 2010, 16:502-515.
220. Lopez S., Turle-Lorenzo N., Acher F., De Leonibus E., Mele A., Amalric M. Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. J. Neurosci. 2007, 27:6701-6711.
221. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., Varney M.A. Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003, 117:697-706.
222. Lorrain D.S., Baccei C.S., Correa L.D., Bristow L.J. Comparison of the effects of diazepam, the CRF1 antagonist CP-154,526 and the group II mGlu receptor agonist LY379268 on stress-evoked extracellular norepinephrine levels. Neuropharmacology 2005, 48:927-935.
223. Lorrain D.S., Schaffhauser H., Campbell U.C., Baccei C.S., Correa L.D., Rowe B., Rodriguez D.E., Anderson J.J., Varney M.A., Pinkerton A.B., Vernier J.M., Bristow L.J. Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. Neuropsychopharmacology 2003, 28:1622-1632.
224. Losonczy A., Somogyi P., Nusser Z. Reduction of excitatory postsynaptic responses by persistently active metabotropic glutamate receptors in the hippocampus. J. Neurophysiol. 2003, 89:1910-1919.
225. Lou X.Y., Ma J.Z., Sun D., Payne T.J., Li M.D. Fine mapping of a linkage region on chromosome 17p13 reveals that GABARAP and DLG4 are associated with vulnerability to nicotine dependence in European-Americans. Hum. Mol. Genet. 2007, 16:142-153.
226. Lynch G., Larson J., Kelso S., Barrionuevo G., Schottler F. Intracellular injections of EGTA block induction of hippocampal long-term potentiation. Nature 1983, 305:719-721.
227. Lynch M.A., Bliss T.V. Noradrenaline modulates the release of [14C]glutamate from dentate but not from CA1/CA3 slices of rat hippocampus. Neuropharmacology 1986, 25:493-498.
228. Machado-Vieira R., Manji H.K., Zarate C.A. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009, 15:525-539.
229. Maciejak P., Taracha E., Lehner M., Szyndler J., Bidzinski A., Skorzewska A., Wislowska A., Zienowicz M., Plaznik A. Hippocampal mGluR1 and consolidation of contextual fear conditioning. Brain Res. Bull. 2003, 62:39-45.
230. Macinnes N., Duty S. Group III metabotropic glutamate receptors act as hetero-receptors modulating evoked GABA release in the globus pallidus in vivo. Eur. J. Pharmacol. 2008, 580:95-99.
231. Maeshima H., Ohnuma T., Sakai Y., Shibata N., Baba H., Ihara H., Higashi M., Ohkubo T., Nozawa E., Abe S., Ichikawa A., Nakano Y., Utsumi Y., Suzuki T., Arai H. Increased plasma glutamate by antipsychotic medication and its relationship to glutaminase 1 and 2 genotypes in schizophrenia-Juntendo University Schizophrenia Projects (JUSP). Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1410-1418.
232. Maj J., Rogoz Z., Skuza G., Jaros T. Some behavioral effects of CNQX AND NBQX, AMPA receptor antagonists. Pol. J. Pharmacol. 1995, 47:269-277.
233. Maj J., Rogoz Z., Skuza G., Kolodziejczyk K. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist. Pol. J. Pharmacol. 1995, 47:501-507.
234. Malek R., Borowicz K.K., Kimber-Trojnar Z., Sobieszek G., Piskorska B., Czuczwar S.J. Remacemide-a novel potential antiepileptic drug. Pol. J. Pharmacol. 2003, 55:691-698.
235. Malinow R., Miller J.P. Postsynaptic hyperpolarization during conditioning reversibly blocks induction of long-term potentiation. Nature 1986, 320:529-530.
236. 2+ concentration by presynaptic glutamate receptors in hippocampus. Br. J. Pharmacol. 1994, 113:1439-1447.
237. Malykh A.G., Sadaie M.R. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs 2010, 70:287-312.
238. Malykhin N.V., Carter R., Seres P., Coupland N.J. Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment. J. Psychiatry Neurosci. 2010, 35:337-343.
239. Manahan-Vaughan D., Reymann K.G. Regional and developmental profile of modulation of hippocampal synaptic transmission and LTP by AP4-sensitive mGluRs in vivo. Neuropharmacology 1995, 34:991-1001.
240. Manji H.K., Lenox R.H. Long-term action of lithium: a role for transcriptional and posttranscriptional factors regulated by protein kinase C. Synapse 1994, 16:11-28.
241. Manji H.K., Moore G.J., Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol. Psychiatry 2000, 48:740-754.
242. Manji H.K., Quiroz J.A., Sporn J., Payne J.L., Denicoff K.N.A.G., Zarate C.A., Charney D.S. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol. Psychiatry 2003, 53:707-742.
243. Marshall K.C., Tsai W.H. Noradrenaline induces short and long duration potentiation of glutamate excitations of cultured Purkinje neurons. Can. J. Physiol. Pharmacol. 1988, 66:848-853.
244. Marti M., Mela F., Bianchi C., Beani L., Morari M. Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors. J. Neurochem. 2002, 83:635-644.
245. Martin-Ruiz R., Puig M.V., Celada P., Shapiro D.A., Roth B.L., Mengod G., Artigas F. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J. Neurosci. 2001, 21:9856-9866.
246. Martin P., Carlsson M.L., Hjorth S. Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats. Neuroreport 1998, 9:2985-2988.
247. Martinez-Coria H., Green K.N., Billings L.M., Kitazawa M., Albrecht M., Rammes G., Parsons C.G., Gupta S., Banerjee P., LaFerla F.M. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am. J. Pathol. 2010, 176:870-880.
248. Martinez G., Ropero C., Funes A., Flores E., Landa A.I., Gargiulo P.A. AP-7 into the nucleus accumbens disrupts acquisition but does not affect consolidation in a passive avoidance task. Physiol. Behav. 2002, 76:205-212.
249. Matrisciano F., Panaccione I., Zusso M., Giusti P., Tatarelli R., Iacovelli L., Mathe A.A., Gruber S.H., Nicoletti F., Girardi P. Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depression: a new strategy to shorten the latency of antidepressant medication?. Mol. Psychiatry 2007, 12:704-706.
250. Matrisciano F., Zusso M., Panaccione I., Turriziani B., Caruso A., Iacovelli L., Noviello L., Togna G., Melchiorri D., Debetto P., Tatarelli R., Battaglia G., Nicoletti F., Giusti P., Girardi P. Synergism between fluoxetine and the mGlu2/3 receptor agonist, LY379268, in an in vitro model for antidepressant drug-induced neurogenesis. Neuropharmacology 2008, 54:428-437.
251. Maura G., Carbone R., Guido M., Pestarino M., Raiteri M. 5-HT2 presynaptic receptors mediate inhibition of glutamate release from cerebellar mossy fibre terminals. Eur. J. Pharmacol. 1991, 202:185-190.
252. McEwen B.S., Chattarji S., Diamond D.M., Jay T.M., Reagan L.P., Svenningsson P., Fuchs E. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol. Psychiatry 2010, 15:237-249.
253. McEwen B.S., Conrad C.D., Kuroda Y., Frankfurt M., Magarinos A.M., McKittrick C. Prevention of stress-induced morphological and cognitive consequences. Eur. Neuropsychopharmacol. 1997, 7(Suppl. 3):S323-S328.
254. McKenna J.E., Melzack R. Blocking NMDA receptors in the hippocampal dentate gyrus with AP5 produces analgesia in the formalin pain test. Exp. Neurol. 2001, 172:92-99.
255. McNamara R.K., Ostrander M., Abplanalp W., Richtand N.M., Benoit S.C., Clegg D.J. Modulation of phosphoinositide-protein kinase C signal transduction by omega-3 fatty acids: implications for the pathophysiology and treatment of recurrent neuropsychiatric illness. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75:237-257.
256. Micheletti G., Lannes B., Haby C., Borrelli E., Kempf E., Warter J.M., Zwiller J. Chronic administration of NMDA antagonists induces D2 receptor synthesis in rat striatum. Brain Res. Mol. Brain Res. 1992, 14:363-368.
257. Miettinen R., Kotti T., Tuunanen J., Toppinen A., Riekkinen P., Halonen T. Hippocampal damage after injection of kainic acid into the rat entorhinal cortex. Brain Res. 1998, 813:9-17.
258. Miguel T.T., Nunes-de-Souza R.L. Defensive-like behaviors and antinociception induced by NMDA injection into the periaqueductal gray of mice depend on nitric oxide synthesis. Brain Res. 2006, 1076:42-48.
259. Mikkelsen J.D., Larsen M.H. Effects of stress and adrenalectomy on activity-regulated cytoskeleton protein (Arc) gene expression. Neurosci. Lett. 2006, 403:239-243.
260. Miyashita T., Williams C.L. Peripheral arousal-related hormones modulate norepinephrine release in the hippocampus via influences on brainstem nuclei. Behav. Brain Res. 2004, 153:87-95.
261. Miyata M., Kashiwadani H., Fukaya M., Hayashi T., Wu D., Suzuki T., Watanabe M., Kawakami Y. Role of thalamic phospholipase C[beta]4 mediated by metabotropic glutamate receptor type 1 in inflammatory pain. J. Neurosci. 2003, 23:8098-8108.
262. Mlinar B., Falsini C., Corradetti R. Pharmacological characterization of 5-HT(1B) receptor-mediated inhibition of local excitatory synaptic transmission in the CA1 region of rat hippocampus. Br. J. Pharmacol. 2003, 138:71-80.
263. Mokler D.J., Dugal J.R., Hoffman J.M., Morgane P.J. Functional interrelations between nucleus raphe dorsalis and nucleus raphe medianus: a dual probe microdialysis study of glutamate-stimulated serotonin release. Brain Res. Bull. 2009, 78:132-138.
264. Moldrich R.X., Giardina S.F., Beart P.M. Group II mGlu receptor agonists fail to protect against various neurotoxic insults induced in murine cortical, striatal and cerebellar granular pure neuronal cultures. Neuropharmacology 2001, 41:19-31.
265. Molinaro G., Traficante A., Riozzi B., Di Menna L., Curto M., Pallottino S., Nicoletti F., Bruno V., Battaglia G. Activation of mGlu2/3 metabotropic glutamate receptors negatively regulates the stimulation of inositol phospholipid hydrolysis mediated by 5-hydroxytryptamine2A serotonin receptors in the frontal cortex of living mice. Mol. Pharmacol. 2009, 76:379-387.
266. Molnar E., Isaac J.T. Developmental and activity dependent regulation of ionotropic glutamate receptors at synapses. Sci. World J. 2002, 2:27-47.
267. Moraes C.L., Bertoglio L.J., Carobrez A.P. Interplay between glutamate and serotonin within the dorsal periaqueductal gray modulates anxiety-related behavior of rats exposed to the elevated plus-maze. Behav. Brain Res. 2008, 194:181-186.
268. Moroni F., Cozzi A., Lombardi G., Sourtcheva S., Leonardi P., Carfi M., Pellicciari R. Presynaptic mGlu1 type receptors potentiate transmitter output in the rat cortex. Eur. J. Pharmacol. 1998, 347:189-195.
269. Morris R.G., Anderson E., Lynch G.S., Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-d-aspartate receptor antagonist, AP5. Nature 1986, 319:774-776.
270. Morris S.H., Knevett S., Lerner E.G., Bindman L.J. Group I mGluR agonist DHPG facilitates the induction of LTP in rat prelimbic cortex in vitro. J. Neurophysiol. 1999, 82:1927-1933.
271. Murphy A.Z., Behbehani M.M. Role of norepinephrine in the interaction between the lateral reticular nucleus and the nucleus raphe magnus: an electrophysiological and behavioral study. Pain 1993, 55:183-193.
272. Murray T.K., Whalley K., Robinson C.S., Ward M.A., Hicks C.A., Lodge D., Vandergriff J.L., Baumbarger P., Siuda E., Gates M., Ogden A.M., Skolnick P., Zimmerman D.M., Nisenbaum E.S., Bleakman D., O'Neill M.J. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J. Pharmacol. Exp. Ther. 2003, 306:752-762.
273. Musazzi L., Milanese M., Farisello P., Zappettini S., Tardito D., Barbiero V.S., Bonifacino T., Mallei A., Baldelli P., Racagni G., Raiteri M., Benfenati F., Bonanno G., Popoli M. Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants. PLoS One 2010, 5:e8566.
274. Myhrer T., Enger S., Aas P. Modulators of metabotropic glutamate receptors microinfused into perirhinal cortex: anticonvulsant effects in rats challenged with soman. Eur. J. Pharmacol. 2010, 636:82-87.
275. Nagai T., Takuma K., Kamei H., Ito Y., Nakamichi N., Ibi D., Nakanishi Y., Murai M., Mizoguchi H., Nabeshima T., Yamada K. Dopamine D1 receptors regulate protein synthesis-dependent long-term recognition memory via extracellular signal-regulated kinase 1/2 in the prefrontal cortex. Learn. Mem. 2007, 14:117-125.
276. Naie K., Tsanov M., Manahan-Vaughan D. Group I metabotropic glutamate receptors enable two distinct forms of long-term depression in the rat dentate gyrus in vivo. Eur. J. Neurosci. 2007, 25:3264-3275.
277. Nair V.D., Savelli J.E., Mishra R.K. Modulation of dopamine D2 receptor expression by an NMDA receptor antagonist in rat brain. J. Mol. Neurosci. 1998, 11:121-126.
278. Nakamura K., Kurasawa M. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur. J. Pharmacol. 2001, 420:33-43.
279. Nakamura K., Tanaka Y. Antidepressant-like effects of aniracetam in aged rats and its mode of action. Psychopharmacology (Berl) 2001, 158:205-212.
280. Navarro J.F., De Castro V., Martin-Lopez M. JNJ16259685, a selective mGlu1 antagonist, suppresses isolation-induced aggression in male mice. Eur. J. Pharmacol. 2008, 586:217-220.
281. Navarro J.F., Postigo D., Martin M., Buron E. Antiaggressive effects of MPEP, a selective antagonist of mGlu5 receptors, in agonistic interactions between male mice. Eur. J. Pharmacol. 2006, 551:67-70.
282. Nemeth H., Toldi J., Vecsei L. Role of kynurenines in the central and peripheral nervous systems. Curr. Neurovasc. Res. 2005, 2:249-260.
283. Nicholas A.P., Pieribone V.A., Arvidsson U., Hokfelt T. Serotonin-, substance P- and glutamate/aspartate-like immunoreactivities in medullo-spinal pathways of rat and primate. Neuroscience 1992, 48:545-559.
284. Nikiforuk A., Popik P., Drescher K.U., van Gaalen M.M., Relo A.L., Mezler M., Marek G., Schoemaker H., Gross G., Bespalov A. Effects of a positive allosteric modulator of mGlu2 receptors LY487379 on cognitive flexibility and impulsive-like responding in rats. J. Pharmacol. Exp. Ther. 2010, 335(3):665-673.
285. Nutt D.J. The role of dopamine and norepinephrine in depression and antidepressant treatment. J. Clin. Psychiatry 2006, 67(Suppl. 6):3-8.
286. O'Connor V., El Far O., Bofill-Cardona E., Nanoff C., Freissmuth M., Karschin A., Airas J.M., Betz H., Boehm S. Calmodulin dependence of presynaptic metabotropic glutamate receptor signaling. Science 1999, 286:1180-1184.
287. O'Donnell P., Grace A.A. Phencyclidine interferes with the hippocampal gating of nucleus accumbens neuronal activity in vivo. Neuroscience 1998, 87:823-830.
288. O'Neill M.J., Bleakman D., Zimmerman D.M., Nisenbaum E.S. AMPA receptor potentiators for the treatment of CNS disorders. Curr. Drug Targets CNS Neurol. Disord. 2004, 3:181-194.
289. O'Neill M.J., Witkin J.M. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr. Drug Targets 2007, 8:603-620.
290. Ogawa M., Shigeto H., Yamamoto T., Oya Y., Wada K., Nishikawa T., Kawai M. d-Cycloserine for the treatment of ataxia in spinocerebellar degeneration. J. Neurol. Sci. 2003, 210:53-56.
291. Okumura T., Kishi T., Okochi T., Ikeda M., Kitajima T., Yamanouchi Y., Kinoshita Y., Kawashima K., Tsunoka T., Inada T., Ozaki N., Iwata N. Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population. Neuropsychobiology 2010, 61:57-63.
292. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., Sesma M.A. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991, 254:1515-1518.
293. Ossowska K., Konieczny J., Wardas J., Golembiowska K., Wolfarth S., Pilc A. The role of striatal metabotropic glutamate receptors in Parkinson's disease. Amino Acids 2002, 23:193-198.
294. Ottersen O.P., Storm-Mathisen J. Glutamate- and GABA-containing neurons in the mouse and rat brain, as demonstrated with a new immunocytochemical technique. J. Comp. Neurol. 1984, 229:374-392.
295. Packard M.G., Teather L.A. Double dissociation of hippocampal and dorsal-striatal memory systems by posttraining intracerebral injections of 2-amino-5-phosphonopentanoic acid. Behav. Neurosci. 1997, 111:543-551.
296. Pae C.U., Park M.H., Marks D.M., Han C., Patkar A.A., Masand P.S. Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. Curr. Opin. Invest. Drugs 2009, 10:75-90.
297. Paes-de-Carvalho R., de Mattos J.C. Development of nitric oxide synthase in the avian retina. Rev. Bras. Biol. 1996, 56(Su 1 Pt 1):145-152.
298. Page G., Peeters M., Najimi M., Maloteaux J.M., Hermans E. Modulation of the neuronal dopamine transporter activity by the metabotropic glutamate receptor mGluR5 in rat striatal synaptosomes through phosphorylation mediated processes. J. Neurochem. 2001, 76:1282-1290.
299. Page M.E., Szeliga P., Gasparini F., Cryan J.F. Blockade of the mGlu5 receptor decreases basal and stress-induced cortical norepinephrine in rodents. Psychopharmacology (Berl) 2005, 179:240-246.
300. Pallotta M., Segieth J., Whitton P.S. N-methyl-d-aspartate receptors regulate 5-HT release in the raphe nuclei and frontal cortex of freely moving rats: differential role of 5-HT1A autoreceptors. Brain Res. 1998, 783:173-178.
301. Palucha-Poniewiera A., Branski P., Lenda T., Pilc A. The antidepressant-like action of metabotropic glutamate 7 receptor agonist N,N'-bis(diphenylmethyl)-1,2-ethanediamine (AMN082) is serotonin-dependent. J. Pharmacol. Exp. Ther. 2010, 334:1066-1074.
302. Palucha A., Tatarczynska E., Branski P., Szewczyk B., Wieronska J.M., Klak K., Chojnacka-Wojcik E., Nowak G., Pilc A. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology 2004, 46:151-159.
303. Pan Y., Berman Y., Carr K.D. Effects of the group I metabotropic glutamate receptor agonist. DHPG, and injection stress on striatal cell signaling in food-restricted and ad libitum fed rats. BMC Neurosci. 2004, 5:50.
304. Paolucci E., Berretta N., Tozzi A., Bernardi G., Mercuri N.B. Depression of mGluR-mediated IPSCs by 5-HT in dopamine neurons of the rat substantia nigra pars compacta. Eur. J. Neurosci. 2003, 18:2743-2750.
305. Pap A., Bradberry C.W. Excitatory amino acid antagonists attenuate the effects of cocaine on extracellular dopamine in the nucleus accumbens. J. Pharmacol. Exp. Ther. 1995, 274:127-133.
306. Patel S., Chapman A.G., Graham J.L., Meldrum B.S., Frey P. Anticonvulsant activity of the NMDA antagonists, d(-)4-(3-phosphonopropyl) piperazine-2-carboxylic acid (d-CPP) and d(-)(E)-4-(3-phosphonoprop-2-enyl) piperazine-2-carboxylic acid (d-CPPene) in a rodent and a primate model of reflex epilepsy. Epilepsy Res. 1990, 7:3-10.
307. Petkov V.D., Grahovska T., Petkov V.V., Konstantinova E., Stancheva S. Changes in the brain biogenic monoamines of rats, induced by piracetam and aniracetam. Acta Physiol. Pharmacol. Bulg. 1984, 10:6-15.
308. Piccinin S., Cinque C., Calo L., Molinaro G., Battaglia G., Maggi L., Nicoletti F., Melchiorri D., Eusebi F., Massey P.V., Bashir Z.I. Interaction between Ephrins and mGlu5 metabotropic glutamate receptors in the induction of long-term synaptic depression in the hippocampus. J. Neurosci. 2010, 30:2835-2843.
309. Pickard G.E., Smith B.N., Belenky M., Rea M.A., Dudek F.E., Sollars P.J. 5-HT1B receptor-mediated presynaptic inhibition of retinal input to the suprachiasmatic nucleus. J. Neurosci. 1999, 19:4034-4045.
310. Pierce R.C., Rebec G.V. Intraneostriatal administration of glutamate antagonists increases behavioral activation and decreases neostriatal ascorbate via nondopaminergic mechanisms. J. Neurosci. 1993, 13:4272-4280.
311. Pieta Dias C., Martins de Lima M.N., Presti-Torres J., Dornelles A., Garcia V.A., Siciliani Scalco F., Rewsaat Guimaraes M., Constantino L., Budni P., Dal-Pizzol F., Schroder N. Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats. Neuroscience 2007, 146:1719-1725.
312. Pilc A., Chaki S., Nowak G., Witkin J.M. Mood disorders: regulation by metabotropic glutamate receptors. Biochem. Pharmacol. 2008, 75:997-1006.
313. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008, 33:88-109.
314. Poschel B., Manahan-Vaughan D. Group II mGluR-induced long term depression in the dentate gyrus in vivo is NMDA receptor-independent and does not require protein synthesis. Neuropharmacology 2005, 49(Suppl 1):1-12.
315. Pralong E., Jones R.S. Interactions of dopamine with glutamate- and GABA-mediated synaptic transmission in the rat entorhinal cortex in vitro. Eur. J. Neurosci. 1993, 5:760-767.
316. Pralong E., Magistretti P., Stoop R. Cellular perspectives on the glutamate-monoamine interactions in limbic lobe structures and their relevance for some psychiatric disorders. Prog. Neurobiol. 2002, 67:173-202.
317. Qi J., Wang Y., Jiang M., Warren P., Chen G. Cyclothiazide induces robust epileptiform activity in rat hippocampal neurons both in vitro and in vivo. J. Physiol. 2006, 571:605-618.
318. Quillfeldt J.A., Schmitz P.K., Walz R., Bianchin M., Zanatta M.S., Medina J.H., Izquierdo I. CNQX infused into entorhinal cortex blocks memory expression, and AMPA reverses the effect. Pharmacol. Biochem. Behav. 1994, 48:437-440.
319. Quintela B.A., Duran R., Alfonso M. Mediation of ionotropic glutamate receptors in domoic acid-induced striatal dopamine release in rats. Eur. J. Pharmacol. 2000, 401:173-177.
320. Quintero J.E., McMahon D.G. Serotonin modulates glutamate responses in isolated suprachiasmatic nucleus neurons. J. Neurophysiol. 1999, 82:533-539.
321. Quirk J.C., Nisenbaum E.S. LY404187: a novel positive allosteric modulator of AMPA receptors. CNS Drug Rev. 2002, 8:255-282.
322. Rao Y., Xiao P., Xu S. Effects of intrahippocampal aniracetam treatment on Y-maze avoidance learning performance and behavioral long-term potentiation in dentate gyrus in rat. Neurosci. Lett. 2001, 298:183-186.
323. Reines A., Cereseto M., Ferrero A., Bonavita C., Wikinski S. Neuronal cytoskeletal alterations in an experimental model of depression. Neuroscience 2004, 129:529-538.
324. Reines A., Cereseto M., Ferrero A., Sifonios L., Podesta M.F., Wikinski S. Maintenance treatment with fluoxetine is necessary to sustain normal levels of synaptic markers in an experimental model of depression: correlation with behavioral response. Neuropsychopharmacology 2008, 33:1896-1908.
325. Reynolds S.M., Berridge K.C. Glutamate motivational ensembles in nucleus accumbens: rostrocaudal shell gradients of fear and feeding. Eur. J. Neurosci. 2003, 17:2187-2200.
326. Rijkers K., Mescheriakova J., Majoie M., Lemmens E., van Wijk X., Philippens M., Van Kranen-Mastenbroek V., Schijns O., Vles J., Hoogland G. Polymorphisms in CACNA1E and Camk2d are associated with seizure susceptibility of Sprague-Dawley rats. Epilepsy Res. 2010, 91:28-34.
327. Robinson D.M., Keating G.M. Memantine: a review of its use in Alzheimer's disease. Drugs 2006, 66:1515-1534.
328. Rodrigues S.M., Bauer E.P., Farb C.R., Schafe G.E., LeDoux J.E. The group I metabotropic glutamate receptor mGluR5 is required for fear memory formation and long-term potentiation in the lateral amygdala. J. Neurosci. 2002, 22:5219-5229.
329. Rodriguez-Borrero E., Bernardo Colon A., Burgos-Martir M.A., Alvarez Carillo J.E., del Campo Y.E., Abella-Ramirez C., Maldonado-Vlaar C.S. NMDA antagonist AP-5 increase environmentally induced cocaine-conditioned locomotion within the nucleus accumbens. Pharmacol. Biochem. Behav. 2006, 85:178-184.
330. Rubinfeld H., Seger R. The ERK cascade: a prototype of MAPK signaling. Mol. Biotechnol. 2005, 31:151-174.
331. Rudy J.W., Matus-Amat P. DHPG activation of group 1 mGluRs in BLA enhances fear conditioning. Learn. Mem. 2009, 16:421-425.
332. Ruhe H.G., Mason N.S., Schene A.H. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol. Psychiatry 2007, 12:331-359.
333. Saarela J., Kallio S.P., Chen D., Montpetit A., Jokiaho A., Choi E., Asselta R., Bronnikov D., Lincoln M.R., Sadovnick A.D., Tienari P.J., Koivisto K., Palotie A., Ebers G.C., Hudson T.J., Peltonen L. PRKCA and multiple sclerosis: association in two independent populations. PLoS Genet. 2006, 2:e42.
334. Saido T.C., Sorimachi H., Suzuki K. Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J. 1994, 8:814-822.
335. Salt T.E. Modulation of NMDA receptor-mediated responses by glycine and d-serine in the rat thalamus in vivo. Brain Res. 1989, 481:403-406.
336. Salt T.E., Eaton S.A. Functions of ionotropic and metabotropic glutamate receptors in sensory transmission in the mammalian thalamus. Prog. Neurobiol. 1996, 48:55-72.
337. Salt T.E., Eaton S.A., Turner J.P. Characterization of the metabotropic glutamate receptors (mGluRs) which modulate GABA-mediated inhibition in the ventrobasal thalamus. Neurochem. Int. 1996, 29:317-322.
338. Sanchez-Camacho C., Bovolenta P. Emerging mechanisms in morphogen-mediated axon guidance. Bioessays 2009, 31:1013-1025.
339. Santos S.D., Carvalho A.L., Caldeira M.V., Duarte C.B. Regulation of AMPA receptors and synaptic plasticity. Neuroscience 2009, 158:105-125.
340. Sasabe J., Chiba T., Yamada M., Okamoto K., Nishimoto I., Matsuoka M., Aiso S. d-Serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis. EMBO J. 2007, 26:4149-4159.
341. Sato T., Tanaka K., Ohnishi Y., Teramoto T., Irifune M., Nishikawa T. Inhibitory effects of group II mGluR-related drugs on memory performance in mice. Physiol. Behav. 2004, 80:747-758.
342. Savoye C., Laurent C., Amadeo S., Gheysen F., Leboyer M., Lejeune J., Zarifian E., Mallet J. No association between dopamine D1, D2, and D3 receptor genes and manic-depressive illness. Biol. Psychiatry 1998, 44:644-647.
343. Scanziani M., Gahwiler B.H., Thompson S.M. Presynaptic inhibition of excitatory synaptic transmission mediated by alpha adrenergic receptors in area CA3 of the rat hippocampus in vitro. J. Neurosci. 1993, 13:5393-5401.
344. Schafer M.K., Varoqui H., Defamie N., Weihe E., Erickson J.D. Molecular cloning and functional identification of mouse vesicular glutamate transporter 3 and its expression in subsets of novel excitatory neurons. J. Biol. Chem. 2002, 277:50734-50748.
345. Scharfman H.E., Goodman J.H., Schwarcz R. Electrophysiological effects of exogenous and endogenous kynurenic acid in the rat brain: studies in vivo and in vitro. Amino Acids 2000, 19:283-297.
346. Schiapparelli L., Del Rio J., Frechilla D. Serotonin 5-HT receptor blockade enhances Ca(2+)/calmodulin-dependent protein kinase II function and membrane expression of AMPA receptor subunits in the rat hippocampus: implications for memory formation. J. Neurochem. 2005, 94:884-895.
347. Schilstrom B., Konradsson-Geuken A., Ivanov V., Gertow J., Feltmann K., Marcus M.M., Jardemark K., Svensson T.H. Effects of S-citalopram, citalopram, and R-citalopram on the firing patterns of dopamine neurons in the ventral tegmental area, N-methyl-d-aspartate receptor-mediated transmission in the medial prefrontal cortex and cognitive function in the rat. Synapse 2010.
348. Schlaepfer I.R., Clegg H.V., Corley R.P., Crowley T.J., Hewitt J.K., Hopfer C.J., Krauter K., Lessem J., Rhee S.H., Stallings M.C., Wehner J.M., Young S.E., Ehringer M.A. The human protein kinase C gamma gene (PRKCG) as a susceptibility locus for behavioral disinhibition. Addict. Biol. 2007, 12:200-209.
349. Schmidt C.J., Fadayel G.M. Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. J. Pharmacol. Exp. Ther. 1996, 277:1541-1549.
350. Schmitz D., Empson R.M., Gloveli T., Heinemann U. Serotonin reduces synaptic excitation of principal cells in the superficial layers of rat hippocampal-entorhinal cortex combined slices. Neurosci. Lett. 1995, 190:37-40.
351. Schmitz D., Gloveli T., Empson R.M., Heinemann U. Serotonin reduces polysynaptic inhibition via 5-HT1A receptors in the superficial entorhinal cortex. J. Neurophysiol. 1998, 80:1116-1121.
352. Schwarcz R., Coyle J.T. Striatal lesions with kainic acid: neurochemical characteristics. Brain Res. 1977, 127:235-249.
353. Schwartz A.R., Pizon A.F., Brooks D.E. Dextromethorphan-induced serotonin syndrome. Clin. Toxicol. (Phila) 2008, 46:771-773.
354. Schwarz P.B., Yee N., Mir S., Peever J.H. Noradrenaline triggers muscle tone by amplifying glutamate-driven excitation of somatic motoneurones in anaesthetized rats. J. Physiol. 2008, 586:5787-5802.
355. Schwier C., Kliem A., Boettger M.K., Bar K.J. Increased cold-pain thresholds in major depression. J. Pain 2010, 11:287-290.
356. Serretti A., Chiesa A., Calati R., Massat I., Linotte S., Kasper S., Lecrubier Y., Antonijevic I., Forray C., Snyder L., Bollen J., Zohar J., De Ronchi D., Souery D., Mendlewicz J. A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. J. Affect Disord. 2011, 128(1-2):56-63.
357. Serretti A., Kato M., Kennedy J.L. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J. 2008, 8:90-100.
358. Sharp P.E. Complimentary roles for hippocampal versus subicular/entorhinal place cells in coding place, context, and events. Hippocampus 1999, 9:432-443.
359. Sheardown M.J. A new and specific non-NMDA receptor antagonist, FG 9065, blocks L-AP4-evoked depolarization in rat cerebral cortex. Eur. J. Pharmacol. 1988, 148:471-474.
360. Shelton R.C., Sanders-Bush E., Manier D.H., Lewis D.A. Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience 2009, 158:1406-1415.
361. Shleper M., Kartvelishvily E., Wolosker H. d-Serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices. J. Neurosci. 2005, 25:9413-9417.
362. Shreve P.E., Uretsky N.J. Role of quisqualic acid receptors in the hypermotility response produced by the injection of AMPA into the nucleus accumbens. Pharmacol. Biochem. Behav. 1988, 30:379-384.
363. Shukitt-Hale B., Lau F.C., Carey A.N., Galli R.L., Spangler E.L., Ingram D.K., Joseph J.A. Blueberry polyphenols attenuate kainic acid-induced decrements in cognition and alter inflammatory gene expression in rat hippocampus. Nutr. Neurosci. 2008, 11:172-182.
364. Siebzehnrubl F.A., Blumcke I. Neurogenesis in the human hippocampus and its relevance to temporal lobe epilepsies. Epilepsia 2008, 49(Suppl. 5):55-65.
365. Silverstein F.S., Chen R., Johnston M.V. The glutamate analogue quisqualic acid is neurotoxic in striatum and hippocampus of immature rat brain. Neurosci. Lett. 1986, 71:13-18.
366. Singer J.H., Bellingham M.C., Berger A.J. Presynaptic inhibition of glutamatergic synaptic transmission to rat motoneurons by serotonin. J. Neurophysiol. 1996, 76:799-807.
367. Skaper S.D. Poly(ADP-ribose) polymerase-1 in acute neuronal death and inflammation: a strategy for neuroprotection. Ann. N.Y. Acad. Sci. 2003, 993:217-228. discussion 287-218.
368. Skolnick P., Popik P., Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol. Sci. 2009, 30:563-569.
369. Smith G.S., Schloesser R., Brodie J.D., Dewey S.L., Logan J., Vitkun S.A., Simkowitz P., Hurley A., Cooper T., Volkow N.D., Cancro R. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 1998, 18:18-25.
370. Spanagel R., Eilbacher B., Wilke R. Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat-a pharmacokinetic microdialysis study. Eur. J. Pharmacol. 1994, 262:21-26.
371. Sperk G., Berger M., Hortnagl H., Hornykiewicz O. Kainic acid-induced changes of serotonin and dopamine metabolism in the striatum and substantia nigra of the rat. Eur. J. Pharmacol. 1981, 74:279-286.
372. Spignoli G., Pedata F., Giovannelli L., Banfi S., Moroni F., Pepeu G. Effect of oxiracetam and piracetam on central cholinergic mechanisms and active-avoidance acquisition. Clin. Neuropharmacol. 1986, 9(Suppl. 3):S39-S47.
373. Stancheva S.L., Alova L.G. Effect of centrophenoxine, piracetam and aniracetam on the monoamine oxidase activity in different brain structures of rats. Farmakol. Toksikol. 1988, 51:16-18.
374. Staubli U., Otaky N. Serotonin controls the magnitude of LTP induced by theta bursts via an action on NMDA-receptor-mediated responses. Brain Res. 1994, 643:10-16.
375. Steckler T., Lavreysen H., Oliveira A.M., Aerts N., Van Craenendonck H., Prickaerts J., Megens A., Lesage A.S. Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test. Psychopharmacology (Berl) 2005, 179:198-206.
376. Steckler T., Oliveira A.F., Van Dyck C., Van Craenendonck H., Mateus A.M., Langlois X., Lesage A.S., Prickaerts J. Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial Water maze task. Behav. Brain Res. 2005, 164:52-60.
377. Stepien A., Chalimoniuk M., Strosznajder J. Serotonin 5HT1B/1D receptor agonists abolish NMDA receptor-evoked enhancement of nitric oxide synthase activity and cGMP concentration in brain cortex slices. Cephalalgia 1999, 19:859-865.
378. Steward O., Worley P. Local synthesis of proteins at synaptic sites on dendrites: role in synaptic plasticity and memory consolidation?. Neurobiol. Learn. Mem. 2002, 78:508-527.
379. Steward O., Worley P.F. Selective targeting of newly synthesized Arc mRNA to active synapses requires NMDA receptor activation. Neuron 2001, 30:227-240.
380. Stohr T., Kupferberg H.J., Stables J.P., Choi D., Harris R.H., Kohn H., Walton N., White H.S. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res. 2007, 74:147-154.
381. Storozhuk V.M., Sanzharovsky A.V., Sachenko V.V. Interaction of glutamatergic and adrenergic inputs of cortical neurons during conditioning. Neuroscience 1997, 76:877-890.
382. Stratford T.R., Swanson C.J., Kelley A. Specific changes in food intake elicited by blockade or activation of glutamate receptors in the nucleus accumbens shell. Behav. Brain Res. 1998, 93:43-50.
383. Suzuki K., Mori N., Kittaka H., Iwata Y., Yamada Y., Osonoe K., Niwa S. Anticonvulsant action of metabotropic glutamate receptor agonists in kindled amygdala of rats. Neurosci. Lett. 1996, 204:41-44.
384. Svoboda P., Teisinger J., Novotny J., Bourova L., Drmota T., Hejnova L., Moravcova Z., Lisy V., Rudajev V., Stohr J., Vokurkova A., Svandova I., Durchankova D. Biochemistry of transmembrane signaling mediated by trimeric G proteins. Physiol. Res. 2004, 53(Suppl 1):S141-S152.
385. Swanson C.J., Perry K.W., Schoepp D.D. The mGlu2/3 receptor agonist, LY354740, blocks immobilization-induced increases in noradrenaline and dopamine release in the rat medial prefrontal cortex. J. Neurochem. 2004, 88:194-202.
386. Tang E., Yip P.K., Chapman A.G., Jane D.E., Meldrum B.S. Prolonged anticonvulsant action of glutamate metabotropic receptor agonists in inferior colliculus of genetically epilepsy-prone rats. Eur. J. Pharmacol. 1997, 327:109-115.
387. Tanti A., Belzung C. Open questions in current models of antidepressant action. Br. J. Pharmacol. 2010, 159:1187-1200.
388. Tata D.A., Yamamoto B.K. Interactions between methamphetamine and environmental stress: role of oxidative stress, glutamate and mitochondrial dysfunction. Addiction 2007, 102(Suppl. 1):49-60.
389. Tatarczynska E., Klodzinska A., Kroczka B., Chojnacka-Wojcik E., Pilc A. The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology (Berl) 2001, 158:94-99.
390. Tatarczynska E., Palucha A., Szewczyk B., Chojnacka-Wojcik E., Wieronska J., Pilc A. Anxiolytic- and antidepressant-like effects of group III metabotropic glutamate agonist (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) in rats. Pol. J. Pharmacol. 2002, 54:707-710.
391. Taylor R.C., Cullen S.P., Martin S.J. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 2008, 9:231-241.
392. Terhaar J., Boettger M.K., Schwier C., Wagner G., Israel A.K., Bar K.J. Increased sensitivity to heat pain after sad mood induction in female patients with major depression. Eur. J. Pain 2010, 14:559-563.
393. Thomas G.M., Huganir R.L. MAPK cascade signalling and synaptic plasticity. Nat. Rev. Neurosci. 2004, 5:173-183.
394. Thomas M.J., Moody T.D., Makhinson M., O'Dell T.J. Activity-dependent beta-adrenergic modulation of low frequency stimulation induced LTP in the hippocampal CA1 region. Neuron 1996, 17:475-482.
395. Thome J., Duman R.S., Henn F.A. Molecular aspects of antidepressive therapy. Transsynaptic effects on signal transduction, gene expression and neuronal plasticity. Nervenarzt 2002, 73:595-599.
396. Thompson K.J., Mata M.L., Orfila J.E., Barea-Rodriguez E.J., Martinez J.L. Metabotropic glutamate receptor antagonist AIDA blocks induction of mossy fiber-CA3 LTP in vivo. J. Neurophysiol. 2005, 93:2668-2673.
397. Thomsen C., Pekhletski R., Haldeman B., Gilbert T.A., O'Hara P., Hampson D.R. Cloning and characterization of a metabotropic glutamate receptor, mGluR4b. Neuropharmacology 1997, 36:21-30.
398. Tizzano J.P., Griffey K.I., Schoepp D.D. The anxiolytic action of mGlu2/3 receptor agonist. LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam. Pharmacol. Biochem. Behav. 2002, 73:367-374.
399. Togashi H., Nakamura K., Matsumoto M., Ueno K., Ohashi S., Saito H., Yoshioka M. Aniracetam enhances glutamatergic transmission in the prefrontal cortex of stroke-prone spontaneously hypertensive rats. Neurosci. Lett. 2002, 320:109-112.
400. Tokarski K., Bobula B., Wabno J., Hess G. Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex. Neuroscience 2008, 153:789-795.
401. Torres-Escalante J.L., Barral J.A., Ibarra-Villa M.D., Perez-Burgos A., Gongora-Alfaro J.L., Pineda J.C. 5-HT1A, 5-HT2, and GABAB receptors interact to modulate neurotransmitter release probability in layer 2/3 somatosensory rat cortex as evaluated by the paired pulse protocol. J. Neurosci. Res. 2004, 78:268-278.
402. Truffinet P., Tamminga C.A., Fabre L.F., Meltzer H.Y., Riviere M.E., Papillon-Downey C. Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am. J. Psychiatry 1999, 156:419-425.
403. Trullas R., Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 1990, 185:1-10.
404. Tsai S.J., Hong C.J., Cheng C.Y., Liao D.L., Liou Y.J. Association study of polymorphisms in post-synaptic density protein 95 (PSD-95) with schizophrenia. J. Neural Transm. 2007, 114:423-426.
405. Turner J.H., Gelasco A.K., Raymond J.R. Calmodulin interacts with the third intracellular loop of the serotonin 5-hydroxytryptamine1A receptor at two distinct sites: putative role in receptor phosphorylation by protein kinase C. J. Biol. Chem. 2004, 279:17027-17037.
406. Turner J.H., Raymond J.R. Interaction of calmodulin with the serotonin 5-hydroxytryptamine2A receptor. A putative regulator of G protein coupling and receptor phosphorylation by protein kinase C. J. Biol. Chem. 2005, 280:30741-30750.
407. Uzunov D.P., Zivkovich I., Pirkle W.H., Costa E., Guidotti A. Enantiomeric resolution with a new chiral stationary phase of 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide, a cognition-enhancing benzothiadiazine derivative. J. Pharm. Sci. 1995, 84:937-942.
408. Varnier G., Fedele E., Marchi M., Raiteri M. Intracerebral administration of l-kynurenine decreases N-methyl-d-aspartate receptor-mediated production of cGMP in the cerebellum and hippocampus of unanaesthetized rats subjected to transcerebral microdialysis. Neurosci. Lett. 1999, 266:81-84.
409. Veena J., Srikumar B.N., Raju T.R., Shankaranarayana Rao B.S. Exposure to enriched environment restores the survival and differentiation of new born cells in the hippocampus and ameliorates depressive symptoms in chronically stressed rats. Neurosci. Lett. 2009, 455:178-182.
410. Vellucci S.V., Parrott R.F. Gene expression in the forebrain of dexamethasone-treated pigs: effects on stress neuropeptides in the hypothalamus and hippocampus and glutamate receptor subunits in the hippocampus. Res. Vet. Sci. 2000, 69:25-31.
411. Venero J.L., Santiago M., Tomas-Camardiel M., Matarredona E.R., Cano J., Machado A. DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury. Neuroscience 2002, 113:857-869.
412. Verma A., Moghaddam B. Regulation of striatal dopamine release by metabotropic glutamate receptors. Synapse 1998, 28:220-226.
413. von Gunten A., Fox N.C., Cipolotti L., Ron M.A. A volumetric study of hippocampus and amygdala in depressed patients with subjective memory problems. J. Neuropsychiatry Clin. Neurosci. 2000, 12:493-498.
414. Von Lubitz D.K., Lin R.C., McKenzie R.J., Devlin T.M., McCabe R.T., Skolnick P. A novel treatment of global cerebral ischaemia with a glycine partial agonist. Eur. J. Pharmacol. 1992, 219:153-158.
415. Vosler P.S., Sun D., Wang S., Gao Y., Kintner D.B., Signore A.P., Cao G., Chen J. Calcium dysregulation induces apoptosis-inducing factor release: cross-talk between PARP-1- and calpain-signaling pathways. Exp. Neurol. 2009, 218:213-220.
416. Wang D., Sadee W., Quillan J.M. Calmodulin binding to G protein-coupling domain of opioid receptors. J. Biol. Chem. 1999, 274:22081-22088.
417. Wang X., Sun Y., Sun N., Liu W., Lang X.E., Yang R., Wu C.S., Zhang K.R. Association study between Protein Kinase C gamma gene polymorphism and major depressive disorder. Zhonghua Yi Xue Za Zhi 2010, 90:738-742.
418. Wang X., Zhong P., Gu Z., Yan Z. Regulation of NMDA receptors by dopamine D4 signaling in prefrontal cortex. J. Neurosci. 2003, 23:9852-9861.
419. Wang Y., Zheng F., Zhou X., Sun Z., Wang H. Converging signal on ERK1/2 activity regulates group I mGluR-mediated Arc transcription. Neurosci. Lett. 2009, 460:36-40.
420. Wedzony K., Mackowiak M., Czyrak A., Fijal K., Michalska B. Single doses of MK-801, a non-competitive antagonist of NMDA receptors, increase the number of 5-HT1A serotonin receptors in the rat brain. Brain Res. 1997, 756:84-91.
421. White I.M., Flory G.S., Hooper K.C., Speciale J., Banks D.A., Rebec G.V. Phencyclidine-induced increases in striatal neuron firing in behaving rats: reversal by haloperidol and clozapine. J. Neural. Transm. Gen. Sect. 1995, 102:99-112.
422. Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpe S., Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol. Psychiatry 2005, 10:538-544.
423. Wieronska J.M., Pilc A. Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. Neurochem. Int. 2009, 55:85-97.
424. Winder D.G., Martin K.C., Muzzio I.A., Rohrer D., Chruscinski A., Kobilka B., Kandel E.R. ERK plays a regulatory role in induction of LTP by theta frequency stimulation and its modulation by beta-adrenergic receptors. Neuron 1999, 24:715-726.
425. Wong A.H., Trakalo J., Likhodi O., Yusuf M., Macedo A., Azevedo M.H., Klempan T., Pato M.T., Honer W.G., Pato C.N., Van Tol H.H., Kennedy J.L. Association between schizophrenia and the syntaxin 1A gene. Biol. Psychiatry 2004, 56:24-29.
426. Wong B.Y., Coulter D.A., Choi D.W., Prince D.A. Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-d-aspartate in brain slices. Neurosci. Lett. 1988, 85:261-266.
427. Wright L.K., Pearson E.C., Hammond T.G., Paule M.G. Behavioral effects associated with chronic ketamine or remacemide exposure in rats. Neurotoxicol. Teratol. 2007, 29:348-359.
428. Wu S.Z., Bodles A.M., Porter M.M., Griffin W.S., Basile A.S., Barger S.W. Induction of serine racemase expression and d-serine release from microglia by amyloid beta-peptide. J. Neuroinflamm. 2004, 1:2.
429. Xia Y.F., Kessler M., Arai A.C. Positive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators have different impact on synaptic transmission in the thalamus and hippocampus. J. Pharmacol. Exp. Ther. 2005, 313:277-285.
430. Xia Z., Storm D.R. Calmodulin-regulated adenylyl cyclases and neuromodulation. Curr. Opin. Neurobiol. 1997, 7:391-396.
431. Xu Z., Johnson A.K. Non-NMDA receptor antagonist-induced drinking in rat. Brain Res. 1998, 808:124-127.
432. Yamaguchi S., Donevan S.D., Rogawski M.A. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 1993, 15:179-184.
433. Yang B., Wang Y., Cynader M.S. Synergistic interactions between noradrenaline and glutamate in cytosolic calcium influx in cultured visual cortical neurons. Brain Res. 1996, 721:181-190.
434. Yang Y., Ge W., Chen Y., Zhang Z., Shen W., Wu C., Poo M., Duan S. Contribution of astrocytes to hippocampal long-term potentiation through release of d-serine. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:15194-15199.
435. Yoon M.H., Bae H.B., Choi J.I. Antinociceptive interactions between intrathecal gabapentin and MK801 or NBQX in rat formalin test. J. Korean Med. Sci. 2005, 20:307-312.
436. Yoshimizu T., Chaki S. Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. Biochem. Biophys. Res. Commun. 2004, 315:493-496.
437. Yoshimizu T., Shimazaki T., Ito A., Chaki S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl) 2006, 186:587-593.
438. Yu Y.W., Chen T.J., Wang Y.C., Liou Y.J., Hong C.J., Tsai S.J. Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluoxetine response. Neuropsychobiology 2003, 47:137-140.
439. Yuen E.Y., Jiang Q., Chen P., Gu Z., Feng J., Yan Z. Serotonin 5-HT1A receptors regulate NMDA receptor channels through a microtubule-dependent mechanism. J. Neurosci. 2005, 25:5488-5501.
440. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63:856-864.
441. Zhang B., Yuan Y., Jia Y., Yu X., Xu Q., Shen Y., Shen Y. An association study between polymorphisms in five genes in glutamate and GABA pathway and paranoid schizophrenia. Eur. Psychiatry 2005, 20:45-49.
442. Zhang D.X., Levy W.B. Ketamine blocks the induction of LTP at the lateral entorhinal cortex-dentate gyrus synapses. Brain Res. 1992, 593:124-127.
443. Zhang H.M., Chen S.R., Pan H.L. Effects of activation of group III metabotropic glutamate receptors on spinal synaptic transmission in a rat model of neuropathic pain. Neuroscience 2009, 158:875-884.
444. Zhang J., Xu T.X., Hallett P.J., Watanabe M., Grant S.G., Isacson O., Yao W.D. PSD-95 uncouples dopamine-glutamate interaction in the D1/PSD-95/NMDA receptor complex. J. Neurosci. 2009, 29:2948-2960.
445. Zheng S., Eacker S.M., Hong S.J., Gronostajski R.M., Dawson T.M., Dawson V.L. NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice. J. Clin. Invest. 2010, 120:2446-2456.
446. Zivkovic I., Thompson D.M., Bertolino M., Uzunov D., DiBella M., Costa E., Guidotti A. 7-Chloro-3-methyl-3-4-dihydro-2H-1,2,4 benzothiadiazine S,S-dioxide (IDRA 21): a benzothiadiazine derivative that enhances cognition by attenuating dl-alpha-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization. J. Pharmacol. Exp. Ther. 1995, 272:300-309.
447. Zur Nieden R., Deitmer J.W. The role of metabotropic glutamate receptors for the generation of calcium oscillations in rat hippocampal astrocytes in situ. Cereb. Cortex 2006, 16:676-687.